Immune checkpoint inhibitors in special populations. a focus on advanced lung cancer patients

Immune checkpoint inhibitors (ICIs) have become the standard treatment in non-small cell lung cancer (NSCLC). Four phase III randomized trials have shown that ICIs such as nivolumab, atezolizumab and pembrolizumab significantly improve overall survival (OS) and quality of life (QoL) when compared with docetaxel in patients who have progressed on prior treatment with a platinum doublet [1,2,3,4]. Programmed death-ligand 1 (PD-L1) expression has been the main predictive biomarker explored for response to anti-PD-1/L1 immunotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research